CASP3 and acute lymphoblastic leukemia: This apoptotic pathway was further confirmed by a significant increase in caspase-3 activity in CXCR4-silenced B-ALL cells treated with Dex (Figure 4j), as well as in the presence of CXCR4 antagonist AMD3100 (Figure 4k).